You're one step closer to unlocking our suite of comprehensive and robust tools.
Fill out the form so we can connect you to the right person.
If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.
Roche again delays $4.3B Spark Therapeutics takeover amid regulatory scrutiny
Gauging Supply Chain Risk In Volatile Times
Cannabis: Hashing Out a Budding Industry
IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help
The Market Intelligence Platform
Roche Holding AG again extended its $4.3 billion takeover offer for Spark Therapeutics Inc. to give additional time to U.S. and U.K. regulators to examine the deal.
In March, Roche launched a buyout offer to acquire all outstanding shares of the Philadelphia-based gene-therapy maker for $114.50 apiece. Roche has already extended the offer period several times from the initial April 3 deadline.
The Swiss drugmaker said the offer will now expire at 5 p.m. ET on Dec. 16, unless further extended.